Mantoux test

PreclinicalBiologic

UUniversity College, London

Mantoux test is one of 48 biologic programs targeting Atopic Eczema. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Atopic EczemaActive, not recruiting

Magnetic Resonance Imaging (MRI)Completed

Atopic EczemaPreclinical

Active, not recruiting

Magnetic Resonance Imaging (MRI)Preclinical

Completed

Competition

Competitive Landscape

45 competitors in Atopic Eczema

#DrugCompanyPhaseTrials

Trexall

Jazz Pharmaceuticals

Approved

1 2

Neoral

Anzupgo

Medrol

Olumiant

Otezla

Rinvoq

Daliresp

Revia

Jakafi

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Magnetic Resonance Imaging (MRI)1 trial

Tracking Inflammatory Cells Using Superparamagnetic Particles of Iron Oxide (SPIO) and Magnetic Resonance Imaging (MRI)

Completed·UUniversity of Edinburgh·N/A·NCT01169935·12 enrolled

Atopic Eczema1 trial

Investigating Immune Mechanisms in Atopic Eczema

Withdrawn·UUniversity College, London·N/A·NCT02102841

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Mantoux test. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mantoux test compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mantoux test. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University College, London company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: UUniversity College, London

Mantoux test

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Magnetic Resonance Imaging (MRI)1 trial

Atopic Eczema1 trial

References

Drug Info

Quick Facts

Related News